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INTRODUCTION
Serine hydroxymethyltransferase (EC 2.1.2.1) (SHMT) is a pyridoxal-phosphate (PLP)-dependant enzyme that catalyzes the reversible interconversion of serine and tetrahydrofolate (THF) to glycine and methylenetetrahydrofolate (methyleneTHF) (1,2). This reaction is a primary source of single carbons that are required for cytoplasmic one-carbon metabolism.
SHMT is present in the cytoplasm (cSHMT) and mitochondria of eukaryotic cells, and different genes encode the two SHMT proteins (3) (4) (5) . Both SHMT isozymes are sources of one-carbon units for cytoplasmic one-carbon metabolism (1,3). In the cytoplasm, folate-activated onecarbon units are required for the de novo synthesis of purines and thymidylate, and for the remethylation of homocysteine to methionine (1,6). Mitochondrial one-carbon metabolism is necessary for the conversion of serine to formate (7) and the mitochondrial SHMT enzyme catalyzes the first step in this pathway by converting serine and THF to glycine and methyleneTHF (6, 7) . Formate enters the cytoplasm where it is incorporated into the folate onecarbon pool (1, 3, 4) . The mitochondrial SHMT gene is expressed at similar levels in most mammalian tissues, whereas the cSHMT gene exhibits a dynamic range of tissue-specific expression (5) .
Mammalian SHMT enzymes are 55 kD homotetramers with four active sites per tetramer.
High-resolution structures are available for the human, mouse, and rabbit cSHMT enzymes, some with amino acid and folate substrates bound (8) (9) (10) . All solved cSHMT structures reveal that the enzyme is best described as a dimer of tight, obligate dimers. Each obligate dimer contains two active sites, and catalytically essential amino acid residues from each monomer contribute to both active sites. Tetramer formation results from the relatively weak association 4 of two obligate dimers. Analysis of the mouse cSHMT structure reveals that the tetramer contact surface is small, involving residues 135-137; 154-157, 168-171 and 189-194 of each monomer (9). Prokaryotic SHMT enzymes lack residues that lie at the tetramer interface and are catalytically active as obligate dimers in solution (11, 12) . Mammalian SHMT isozymes are tetramers in solution, but form mixtures of dimers and tetramers in the absence of bound PLP (13) . The dissociation of cSHMT tetramers into obligate dimers in the absence of bound PLP suggests that the catalytic site of the enzyme communicates with amino residues at the tetramer interface. Site-directed mutations that alter amino acid residues near the tetramer interface site, or that decrease the affinity of PLP for the enzyme weaken the interactions between two obligate dimers (13, 14) . For example, recombinant D89N cSHMT from sheep has decreased catalytic activity and is a mixture of dimers and tetramers in solution (14) . Recombinant H134N cSHMT from sheep has decreased affinity for PLP and is present in solution as a mixture of tetramers and dimers (13) . The H134N cSHMT dimers are active, but the specific activity of the enzyme reduced by 75% compared to the nonmutated enzyme under conditions of saturating PLP. This study indicates that tetramer formation is not necessary for cSHMT catalytic activity (13) .
To better understand the stability of cSHMT tetramers and the interaction of subunits within cSHMT tetramers, and to further examine the relationship between tetramer formation and cSHMT activity, we engineered a catalytically inactive, dominant-negative cSHMT enzyme (DNcSHMT). The results from these studies provide evidence that neither monomers nor obligate dimers exchange among preformed cSHMT tetramers in the presence of PLP.
However, loss of cSHMT-bound PLP permits exchange of obligate dimers, but not monomers, among preformed cSHMT tetramers. Furthermore, we show that cSHMT and DNcSHMT for 90 sec with a 10 min extension at 72°C. The DNcSHMT cDNA was generated by replacing the KpnI-BamHI fragment within the human cSHMT cDNA with the PCR product that contains the three codon substitutions. The DNcSHMT cDNA was subcloned into the NdeI and NotI restriction sites of the pET22b expression vector, which confers kanamycin resistance. The cSHMT cDNA was subcloned into pET28a expression vector in frame with the N-terminus 7 polyhistidine tag using the NdeI and NotI restriction sites, and this vector confers ampicillin resistance. The mutated cDNAs were sequence verified. The expression vectors containing the cSHMT and DNcSHMT cDNAs were transformed into competent BL21* bacteria both singly and in combination. One liter cultures of BL21* cells expressing the cSHMT, DNcSHMT or coexpressing cSHMT and DNcSHMT cDNAs were grown to mid log phase and protein synthesis was induced with isopropyl β-D-thiogalactopyranoside for 8 hrs at room temperature. Cell pellets were harvested and stored at -80°C until purification.
Purification of the cSHMT and DNcSHMT proteins. Cell pellets were lysed in a buffer containing 40 mM Kphosphate, pH 7.0, 10 mM 2-mercaptoethanol and 100 nM PLP using a
French press and the insoluble material was removed by centrifugation at 12,000 rpm. For purification of the DNcSHMT protein, the clarified supernatant was applied directly to a CM sepharose ion exchange column (Clontech) and the protein purified to homogeneity as described previously (15) . Recombinant SHMT from either bacteria that expressed the cSHMT protein, or that coexpressed cSHMT and DNcSHMT proteins, was purified by affinity chromatography.
Cell suspensions were centrifuged at 12,000 rpm for 20 min at 4°C to pellet insoluble material.
The cSHMT protein, which contains a N-terminal polyhistidine tag, was purified from the clarified sample on a Talon® metal affinity resin following the manufacturer's instructions (Clontech). The purity of all proteins was determined by SDS-polyacrylamide gel electrophoresis and protein concentrations were determined by a modified Lowry assay (16) .
Purified protein was stored at -80˚C. DNcSHMT-catalyzed cleavage of allothreonine using the coupled enzyme assay with alcohol dehydrogenase as described previously (17) . The rate of absorbance loss at 340 nm was recorded after the addition of 300-2000 pmol of SHMT to a 1 ml cuvette containing 25 mM HEPES, pH 7.2, 10 mM 2-mercaptoethanol, allothreonine, alcohol dehydrogenase, and 0.15 mM NADH in a spectrophotometer (Shimadzu UV-2401PC). L-cysteine (16 mg/ml) was added to a 2 ml solution that contained 3 mg of cSHMT (with an Nterminal polyhistidine tag), 20 mg of DNcSHMT, and 100 mM 2-mercaptoethanol. The solution was incubated at room temperature for 15 min. The protein was precipitated by the addition of ammonium sulfate to 70% saturation, incubated on ice for 5 min, and then centrifuged at 4300 rpm for 20 min. The precipitated protein pellet was suspended in 2 ml of 100 mM L-cysteine, 100 mM 2-mercaptoethanol. This cycle was repeated 3 times and the protein was incubated at 37 o C for 5 min. The procedure lasted 3 h in duration. The protein was then dialyzed for 24 h against 2 l of 20 mM Kphosphate, pH 7.2, 2.5 mM 2-mercaptoethanol, N-terminal polyhistidine tag), 20 mg of DNcSHMT, and 100mM 2-mercaptoethanol and was incubated at room temperature for the duration of the procedure described and stored at 4˚C for the duration of the dialysis described above. After 24 h, both the experimental and control proteins were dialyzed against a buffer containing 10 mM Tris-Cl, pH 7.0, 50 mM NaCl, 50 mM glycine, and 100 nM PLP for 1 hr at 4˚C. The proteins were each purified using the batch/gravity flow protocol for the Talon® metal affinity resin (Clontech) with the following buffers: extraction/wash buffer -10 mM Tris-Cl, pH 7.0, 50 mM NaCl, 50 mM glycine, and PLP; stringent wash buffer -20 mM Tris-Cl, pH 7.0, 50 mM NaCl, 50 mM glycine, PLP, and 
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SDS-polyacrylamide gel electrophoresis.
Purified proteins (1-3 µg) were suspended in buffer containing 2% SDS, 62.5 mM Tris, pH 6.8, 100 mM dithiothreitol and 10% glycerol and then incubated at 100°C for 10 min. The purified proteins were then run on a mini-SDS-PAGE using a 5% stacking gel and 12% separating gel in a slab gel apparatus (Biorad) with the discontinuous buffer system of Laemmli.
RESULTS
Design of a dominant negative SHMT protein.
To study the assembly of cSHMT tetramers and the occurrence of dynamic interchange of cSHMT subunits among cSHMT tetramers, a human DNcSHMT protein was designed using information derived from previous studies of mutated cSHMT proteins, as well as information derived from the murine cSHMT protein crystal structure (9). The murine cSHMT structure was solved with glycine and 5-formylTHF bound at the active site. The cSHMT-gly-5-formylTHF ternary complex is an intermediate state analog of the cSHMT-ser-THF catalytic complex (9), and this structure was used to design rationally a dominant-negative SHMT protein that can inactivate cSHMT activity.
The DNcSHMT protein was designed to: (1) oligomerize with and inactivate recombinant cSHMT monomeric subunits by inhibiting serine and allothreonine cleavage activity, (2) have decreased affinity for folate and (3) retain affinity for PLP. Modeling studies indicated that three amino acid substitutions on a single cSHMT polypeptide were needed to achieve these goals, and these three amino acids are conserved in all known SHMT enzymes (Figure 1, Panel A) . K257 is the active site lysine in the murine and human cSHMTs that forms a Schiff base with the PLP cofactor. Mutation of this active site K to Q inactivates the E. coli cSHMT. The mutated protein can catalyze only a single turnover; this mutation does not allow the expulsion of the amino acid product and therefore subsequent turnover is inhibited. However, this mutant retains affinity for folate cofactors and purifies with a PLP and amino acid bound (20) (Table 1) . Y83 in the human and mouse cSHMT forms a hydrogen bond with the carboxylate of the amino acid substrate, and mutation of the analogous residue in the E. coli SHMT to F decreases the specific activity of the protein by greater than 99% and increases the enzyme's affinity for tetrahydrofolate (Table 1) Figure 2A , lanes 1 and 2 show that both the cSHMT and DNcSHMT proteins can be expressed in E. coli, and that the cSHMT protein can be separated from the DNcSHMT protein by SDS-PAGE because of its increased molecular mass resulting from the polyhistidine tag. Assuming equal concentrations of cSHMT and DNcSHMT monomers (as shown in Figure 2 ), the expected frequency of each potential tetramer was calculated for Models I and II.
Additionally, the activity of each tetramer was predicted by assuming that both DNcSHMT homodimers and DNcSHMT/cSHMT heterodimers are inactive, and that the formation of tetramers from obligate dimers does not influence the activity of either obligate dimer. The expected specific activity of the purified cSHMT/DNcSHMT protein will be the average of the specific activity for each tetrameric isoform, after correcting for its relative abundance. If the complex is reduced to less than 0.1% compared to the cSHMT protein (Table 1) . Other studies have shown that the Y to F mutation eliminates the formation of the glycine quinonoid (Table 1 
Effect of PLP on subunit interchange among cSHMT and DNcSHMT tetramers.
In this study, the affect of PLP on exchange of cSHMT subunits between preformed cSHMT and DNcSHMT tetramers was investigated as described in experimental procedures. Incubation of purified, recombinant cSHMT protein with a 7-fold molar excess DNcSHMT followed by affinity purification of the cSHMT protein did not result in the co-purification of DNcSHMT, indicating that cSHMT subunits do not exchange between preformed cSHMT and DNcSHMT tetramers when PLP is bound (Figure 7, lane 1) . However, when cSHMT and DNcSHMT proteins that lack bound PLP are incubated together, subunit exchange must have occurred because DNcSHMT copurified with cSHMT on the affinity column ( Figure 7, lane 2) . The ratio of cSHMT to DNcSHMT monomers in the purified protein was 63% to 27% respectively, indicating that the subunit exchange had not reached equilibrium. Incubation beyond 3 h was not possible because of the formation of insoluble precipitate, suggesting that cSHMT dimers are unstable.
Because cSHMT monomers have never been isolated and loss of PLP results in the dissociation of tetramers to dimers, it is assumed that loss of PLP permits exchange of obligate homodimers between cSHMT and DNcSHMT tetramers (Figure 3, model II) . To test this hypothesis, absorbance spectra of the purified protein that underwent the subunit exchange reaction were recorded ( Table 2 ). The addition of glycine and 5-formylTHF to this purified protein resulted in the formation of the glycine quinonoid intermediate, with an A 502 nm that was 30% less than that observed for the cSHMT homotetramer ( Table 2 ), indicating that the predicted catalytic competency of the cSHMT enzyme had decreased 30% following the exchange reaction. This This study demonstrates that the activity of cSHMT obligate dimers is not affected by tetramerization with DNcSHMT obligate dimers, a primary assumption in our models (Figure 3 ).
Catalytic activity of cSHMT and DNcSHMT proteins. The catalytic activities of the cSHMT,
DNcSHMT and DNcSHMT/cSHMT tetramers were determined to verify that quinonoid Table 2 verify that the catalytic activity (k cat ) of the enzymes parallel their ability to form glycine quinonoid intermediates, and that the DNcSHMT protein can only inactive cSHMT catalytic function when it dimerizes with cSHMT monomers. 
Conclusions
The generation of a DNcSHMT protein enabled a thorough investigation into the dynamic exchange of subunits among cSHMT tetramers, and the ability of amino acids, folates and PLP to affect subunit exchange among preformed cSHMT tetramers. Furthermore, the study of cSHMT/DNcSHMT heterotetramers gives new insight into the stiochiometry of folate binding and communication among active sites within the tetramer.
Pyridoxal phosphate inhibits dynamic subunit exchange. A polymorphism in the cSHMT gene is associated with altered serum homocysteine levels (a risk for birth defects and certain cancers) (22) and decreased risk for leukemia (23) . Therefore, understanding the factors that regulate cSHMT activity is important to elucidate the mechanisms whereby altered folate metabolism influences risk for diseases and birth defects (1). SHMT activity is decreased in the livers of vitamin B6-deficient rats, and it is presumed that the decreased activity results from the loss of PLP cofactor from the active site and formation of apoenzyme (24) . However, the effect of vitamin B-6 deficiency on SHMT turnover rates has not been investigated. Whereas other studies have demonstrated that loss of PLP from the SHMT active site weakens the interactions of the obligate dimers within the tetramer, this study demonstrates that cSHMT tetramers are very stable and do not exchange subunits unless they lack bound PLP because PLP inhibits this exchange by stabilizing the tetramer. Further investigation is required to determine if cellular PLP deficiency results in increased rates of cSHMT protein turnover resulting from dissociation of cSHMT tetramers.
Communication among cSHMT monomers and obligate dimers. Previous titration calorimetry
studies have demonstrated that only half of the active sites within the cSHMT tetramer bind reduced folates (25) . There are three mechanisms that may account for half-site occupancy 20 within the cSHMT tetramer: (1) half-site occupancy within the obligate dimer, (2) asymmetric obligate dimers with one obligate dimer saturated with folate, the other dimer lacking folate or (3) random binding of two folate molecules per SHMT tetramer. Mechanism 1 implies that only active sites within the obligate dimer communicate, whereas mechanism 2 and 3 assume all four active sites within a tetramer communicate. Mechanism 1 is supported by the report of the Bacillus stearothermophilus SHMT crystal structure (12) . This enzyme is an obligate dimer in solution because it lacks the amino acid residues required for tetramer formation. This enzyme was crystallized with glycine and 5-formylTHF bound, and only one of the active sites within the obligate dimer contained 5-formylTHF. In contrast, the structure of the E. coli cSHMT that was solved with 5-formylTHF and glycine bound does not support mechanism 1 (11); this structure showed 5-formylTHF tightly bound in both active sites of the obligate dimer (11). Mechanism 2 is supported by the report of the E. coli (described above) and murine cSHMT structures that were obtained from crystals grown in the presence of glycine and 5-formylTHF (9). The mouse structure had only two 2 equivalents of 5-formylTHF bound tightly, with one obligate dimer displaying full occupancy of the active sites, and no or disordered folate binding in the other obligate dimer (9), indicating negative cooperativity between the obligate dimers within the tetrameric enzyme. There are no data to support mechanism 3.
The inability of obligate dimers to communicate with each other (mechanism 1) within the cSHMT tetramers was an underlying assumption of our assembly models (Figure 3 ), and these assumptions were supported by the experimental data presented. The data presented here also support mechanism 1 with respect to stiochiometry of folate binding within the tetramer. Loss of PLP results in exchange of obligate dimers between preformed cSHMT and DNcSHMT tetramers ( Figure 3 , Model 2) and a decrease in the specific activity of the cSHMT protein (table 2) . The 34% decrease in the specific activity associated with cSHMT/DNcSHMT heterotetramer formation is fully accounted for by the inclusion of inactive DNcSHMT obligate dimers within the tetramers (Figure 7) , thereby diluting the specific activity of the cSHMT homodimers that exchanged with DNcSHMT homodimers by 50%. If mechanism 2 for folate binding is correct, the concentration of the quinonoid should be the same in tetramers that are formed from two cSHMT homodimers and from cSHMT/DNcSHMT tetramers formed from cSHMT homodimers and DNcSHMT homodimers ( Figure 3, Model 2) . The replacement of an "inactive cSHMT obligate dimer" (that cannot bind folate) within the cSHMT homotetramers with an inactive DNcSHMT obligate dimer should not alter the intensity of the quinonoid within the tetramer.
Furthermore, "inactive cSHMT obligate dimers" should become "activated" following tetramer formation with DNcSHMT homodimers. Therefore, these studies seem to eliminate mechanism 2 with respect to folate binding to cSHMT tetramers in solution. We recognize that this mechanism is not consistent with results from the E. coli and murine SHMT structures, but these results are supported by the structure of the Bacillus stearothermophilus cSHMT enzyme (12) .
Also, we recognize that the ability of cSHMT obligate dimers to communicate within the tetramer may have been lost as a result of minor structural perturbations resulting from the three mutations in the DNcSHMT protein. Approximately 0.85 µg of purified protein was run on a 12% mini-SDS-PAGE using the discontinuous buffer system of Laemmli. The gel was stained with SimplyBlue (Invitrogen) to visualize the proteins. 
